CA3054915A1 - Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker - Google Patents

Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker Download PDF

Info

Publication number
CA3054915A1
CA3054915A1 CA3054915A CA3054915A CA3054915A1 CA 3054915 A1 CA3054915 A1 CA 3054915A1 CA 3054915 A CA3054915 A CA 3054915A CA 3054915 A CA3054915 A CA 3054915A CA 3054915 A1 CA3054915 A1 CA 3054915A1
Authority
CA
Canada
Prior art keywords
marker
subject
cells
cell
ctcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3054915A
Other languages
English (en)
French (fr)
Inventor
Cedric Blanpain
Panagiota SOTIROPOULOU
Ievgenia PASTUSHENKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Original Assignee
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB filed Critical Universite Libre de Bruxelles ULB
Publication of CA3054915A1 publication Critical patent/CA3054915A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3054915A 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker Pending CA3054915A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17161411.8 2017-03-16
EP17161411 2017-03-16
PCT/EP2018/056760 WO2018167312A1 (en) 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Publications (1)

Publication Number Publication Date
CA3054915A1 true CA3054915A1 (en) 2018-09-20

Family

ID=58387669

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3054915A Pending CA3054915A1 (en) 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Country Status (8)

Country Link
US (2) US12123877B2 (https=)
EP (2) EP4235179B1 (https=)
JP (1) JP7278595B2 (https=)
KR (1) KR102583603B1 (https=)
AU (1) AU2018235021B2 (https=)
CA (1) CA3054915A1 (https=)
IL (1) IL269315B2 (https=)
WO (1) WO2018167312A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113009135A (zh) * 2021-02-19 2021-06-22 山东省大健康精准医疗产业技术研究院 一种检测cd47的管式磁微粒化学发光免疫定量试剂盒及其制备方法与应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019202788A1 (de) * 2019-03-01 2020-09-03 Robert Bosch Gmbh Verfahren zum Zählen von Zelltypen oder Zellmarkern in einer Probe, insbesondere in einer Blutprobe
JP2020144054A (ja) * 2019-03-07 2020-09-10 学校法人昭和大学 末梢血循環癌細胞の検出方法及び検出装置
KR102654518B1 (ko) * 2020-05-26 2024-04-04 가톨릭대학교 산학협력단 Lsp1 결핍 t 세포
CA3233047A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US8980568B2 (en) * 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
AU2004286307A1 (en) 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
WO2006130737A1 (en) * 2005-06-02 2006-12-07 Immunivest Corporation A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
CA2628390A1 (en) * 2005-11-02 2007-05-18 The Regents Of The University Of Michigan Molecular profiling of cancer
CA2572530A1 (en) * 2005-12-30 2007-06-30 Centocor, Inc. A method for determining the phenotype of cells
GB0808413D0 (en) 2008-05-09 2008-06-18 Univ Nottingham Stabilisation of blood cell conjugates
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
EP2199798A1 (en) * 2008-12-18 2010-06-23 Universite Libre De Bruxelles Diagnostic method and kit of circulating tumor cells
EP2455403A1 (en) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
CN105102978B (zh) * 2013-02-02 2018-11-02 杜克大学 分离循环肿瘤细胞的方法
AU2014364520B2 (en) * 2013-12-20 2020-01-02 The General Hospital Corporation Methods and assays relating to circulating tumor cells
CN112358943A (zh) * 2015-01-21 2021-02-12 新加坡科技研究局 用于基于大小回收稀有细胞的以柱为基础的装置和方法，及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113009135A (zh) * 2021-02-19 2021-06-22 山东省大健康精准医疗产业技术研究院 一种检测cd47的管式磁微粒化学发光免疫定量试剂盒及其制备方法与应用
CN113009135B (zh) * 2021-02-19 2024-04-02 山东省大健康精准医疗产业技术研究院 一种检测cd47的管式磁微粒化学发光免疫定量试剂盒及其制备方法与应用

Also Published As

Publication number Publication date
EP3596467A1 (en) 2020-01-22
IL269315A (en) 2019-11-28
EP4235179C0 (en) 2025-08-13
EP4235179A3 (en) 2023-11-15
JP2020512549A (ja) 2020-04-23
WO2018167312A1 (en) 2018-09-20
AU2018235021B2 (en) 2024-07-11
EP3596467B1 (en) 2023-09-27
AU2018235021A1 (en) 2019-09-12
EP3596467C0 (en) 2023-09-27
IL269315B1 (en) 2025-01-01
US20210190787A1 (en) 2021-06-24
IL269315B2 (en) 2025-05-01
KR20190142330A (ko) 2019-12-26
EP4235179A2 (en) 2023-08-30
US20250027946A1 (en) 2025-01-23
US12123877B2 (en) 2024-10-22
JP7278595B2 (ja) 2023-05-22
EP4235179B1 (en) 2025-08-13
KR102583603B1 (ko) 2023-10-05

Similar Documents

Publication Publication Date Title
US20250027946A1 (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
Gubin et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
JP6730996B2 (ja) 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
EP3634584B1 (en) Tumor-infiltrating t-cells for use in the treatment of cancer
WO2018089386A1 (en) Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
TW202019480A (zh) 新穎lilrb4抗體及其用途
CN110573180A (zh) 癌症治疗用药物组合物
JP2021527082A (ja) 新規な免疫チェックポイント阻害剤
CA2990520C (en) Methods for detecting tissue infiltrating nk cells
US20240302349A1 (en) Methods of assessing or monitoring a response to a cell therapy
JP2024509530A (ja) 赤血球障害を治療する方法
JP2011516840A (ja) 可溶性ｃｄ２００に関するアッセイ法
US20240418722A1 (en) Methods and kits for diagnosing cancer and predicting response to treatment based on cenp-a labelling
EP4605752A1 (en) Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target
WO2017023971A1 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors
WO2026039869A1 (en) "predicting responders to cancer therapy"
Maio et al. High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients
BR122025004286A2 (pt) Usos de: um anticorpo anti-il-22 ou anti-il-22ra1, um regulador negativo da sinalização da interleucina-22 (il-22), um antagonista de um receptor de hidrocarboneto de arila, um agente que inibe o número de cópias, quantidade e/ou atividade de pelo menos um biomarcador, e métodos: ex vivo ou in vitro para determinar se um indivíduo afligido com ou em risco de desenvolver uma síndrome mielodisplásica (mds) e/ou uma anemia, e para monitorar a eficácia de um regulador negativo da sinalização de il-22 no tratamento de uma mds e/ou anemia
Gwin et al. Immunologic Monitoring in Immuno‐Oncology
Galluzzi et al. An immunosurveillance mechanism controls cancer cell ploidy. Supplementary Material.
Roussy Tumor sialylation controls effective anti-cancer immunity in breast cancer
WO2016201199A1 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230228

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240801

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241230

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250221

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250506

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250905

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309